Non-Alcoholic Steatohepatitis (NASH) Market in Focus: Forecasting Growth Drivers, Scaling Potential, and Global Opportunities
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#What Are the Projected Market Size and Growth Rates for the Non-Alcoholic Steatohepatitis (NASH) Market From 2025 To 2029?#_x000D_
The market size for non-alcoholic steatohepatitis (NASH) has seen a substantial surge in growth in the past few years. Its value is projected to increase from $4.5 billion in 2024 to $6.06 billion in 2025, showcasing a compound annual growth rate (CAGR) of 34.7%. The significant growth experienced during the historical period can be ascribed to factors such as the increasing cases of NASH, escalating obesity crisis, heightened awareness and detection rates, changes in lifestyle and food habits, and advancements in healthcare infrastructure._x000D_
_x000D_
Expectations for the non-alcoholic steatohepatitis (NASH) market show significant expansion in the upcoming years. Notably, it is projected to reach a market size of $18.55 billion by 2029, yielding a compound annual growth rate (CAGR) of 32.3%. This considerable growth can be credited to several factors, including advancements in NASH medication development, the rise in NASH screening initiatives, an increase in healthcare spending, combined research initiatives, and government regulatory support. Key tendencies expected during the forecast period comprise focusing on lifestyle modifications and patient education, fostering collaboration in clinical trials, regulatory progress and pathway designations, as well as the incorporation of artificial intelligence in diagnosis and supervision._x000D_
_x000D_
#Download a free sample to assess the report’s scope and structure:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp_x000D_
_x000D_
#What Are the Core Market Drivers Propelling Growth in the Non-Alcoholic Steatohepatitis (NASH) Industry?#_x000D_
The escalating prevalence of obesity is fuelling the necessity for the non-alcoholic steatohepatitis (NASH) market. Obesity, characterized by abnormal or excessive fat accumulation and a body weight exceeding the standard recommended for a given height, poses a significant health risk. The increasing frequency of non-alcoholic fatty liver disease, owing to the burgeoning obesity crisis, implies that NASH could potentially emerge as the leading cause of serious liver disease in the approaching years, thereby necessitating NASH treatments and associated medications. For example, in March 2024, the World Health Organization (WHO), a UK-based global public health organization, reported that in 2022, nearly 2.5 billion adults, 18 years and older, were identified as overweight, out of which 890 million were diagnosed with obesity. Hence, the surge in obesity cases will propel the expansion of the non-alcoholic steatohepatitis (NASH) market._x000D_
_x000D_
#How Is the Non-Alcoholic Steatohepatitis (NASH) Market Segmented?#_x000D_
The non-alcoholic steatohepatitis (nash) market covered in this report is segmented – _x000D_
_x000D_
1) By Type: Solid, Liquid_x000D_
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products_x000D_
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity_x000D_
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider_x000D_
5) By Application: Oral, Parenteral_x000D_
_x000D_
Subsegments: _x000D_
1) By Solid: Tablets, Capsules, Other Solid Dosage Forms _x000D_
2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms _x000D_
_x000D_
#Request customized data on this market:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=8805&type=smp_x000D_
_x000D_
#Which Regions Are Driving the Next Phase of the Non-Alcoholic Steatohepatitis (NASH) Market Growth?#_x000D_
North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#What Key Market Trends and Innovations Are Shaping the Future of the Non-Alcoholic Steatohepatitis (NASH) Industry?#_x000D_
Major firms in the non-alcoholic steatohepatitis (NASH) industry are advancing thyroid hormone receptor-beta (THR-beta) agonists to improve liver metabolism, decrease fat accumulation in the liver and promote better liver function. These agonists are substances that selectively stimulate the thyroid hormone receptor-beta subtype, playing a crucial role in managing metabolism, growth, and development. For example, Rezdiffra (resmetirom), a thyroid hormone receptor-beta agonist was sanctioned as the first treatment for adults with noncirrhotic NASH with moderate to severe liver fibrosis (scarring) by the Food and Drug Administration, a regulatory agency in the US, in March 2024. Rezdiffra, by selectively triggering the THR-beta receptor, helps in managing lipid metabolism, thus reducing intrahepatic triglycerides and overall fat accumulation in the liver._x000D_
_x000D_
#View the full report here:#_x000D_
_x000D_
#How Is the Non-Alcoholic Steatohepatitis (NASH) Market Defined and What Are Its Core Parameters?#_x000D_
Non-alcoholic steatohepatitis (NASH) is a severe case of fatty liver disease that is characterized by inflammation of the liver and can proceed to cirrhosis and liver failure._x000D_
_x000D_
#Purchase the full report and get a swift delivery:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8805_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Europe +44 7882 955267_x000D_
Asia & Others +44 7882 955267 & +91 8897263534_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
